Capital Impact Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Capital Impact Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-7,605	Closed	-$518K	–	63
2024 Q1	$518K	Sell	7,605 -7,009	-48%	-$502K	0.67%	66
2023 Q4	$915K	Buy	+14,614	New	+$808K	1.2%	33
2023 Q3	–	Sell	-8,205	Closed	-$461K	–	125
2023 Q2	$461K	Hold	8,205	–	–	0.51%	100
2023 Q1	$371K	Buy	+8,205	New	+$399K	0.46%	106
2022 Q1	–	Sell	-3,470	Closed	-$26K	–	191
2021 Q4	$26K	Buy	+3,470	New	+$303K	0.02%	97
2021 Q3	–	Sell	-45,440	Closed	-$7.36M	–	125
2021 Q2	$7.36M	Buy	+45,440	New	+$5.53M	2.37%	3
2020 Q4	–	Sell	-70,000	Closed	-$5.86M	–	107
2020 Q3	$5.86M	Buy	+70,000	New	+$6.21M	1.74%	10

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital Impact Advisors's CRSP Position: Q2 2024 in Review

Capital Impact Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 7,605 shares — an estimated $518K sold.

Capital Impact Advisors first reported a position in CRSP in Q3 2020 and held it in 7 quarters. The position peaked at $7.36M in Q2 2021. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

Capital Impact Advisors reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
Capital Impact Advisors sold 7,605 CRISPR Therapeutics shares in Q2 2024, an estimated $518K.
Capital Impact Advisors first reported a position in CRISPR Therapeutics in Q3 2020 and held it in 7 quarters.
Capital Impact Advisors's CRISPR Therapeutics position peaked at $7.36M in Q2 2021.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on Capital Impact Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.